MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
Sort
Language
Type
Field
Venue
Topic
Prostate Cancer Treatment and Research
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

3,880 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
3,880 works in the cohort · of 4,299,418page 33 of 78

Labels cover 13 of 3,880 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 3,880 of 3,880 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affunlabeled
PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase III trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients with localized high-risk or locally advanced prostate cancer (PC).
Mary‐Ellen Taplin, Martin Gleave, Christopher P. Evans, Eleni Efstathiou, Philip W. Kantoff, Ashley E. Ross +12 more
2020· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
9
citations
affno abstractunlabeled
EGFR ligands exert diverging effects on male reproductive organs
Marlon R. Schneider, Ana Angélica Gratão, Maik Dahlhoff, Auke Boersma, Martin Hrabě de Angelis, Cuong Hoang‐Vu +2 more
2009· article· en· Experimental and Molecular Pathology· Medicine
machine prediction:candidate · noneconsensus · none
9
citations
affno abstractunlabeled
Perspectives on Prostate Cancer Biomarkers
Shahrokh F. Shariat, Pierre I. Karakiewicz
2008· editorial· en· European Urology· Medicine
machine prediction:candidate · noneconsensus · none
9
citations
affunlabeled
Patient (pt) population and radiation therapy (RT) type in the long-term phase 3 double-blind, placebo (PBO)-controlled ATLAS study of apalutamide (APA) added to androgen deprivation therapy (ADT) in high-risk localized or locally advanced prostate cancer (HRLPC).
Howard M. Sandler, Stephen J. Freedland, Neal D. Shore, Rosamerlinda S. Rosales, Sabine Brookman‐May, David P. Dearnaley +13 more
2022· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
9
citations
affunlabeled
Gene of the month: ERG
Dorinda Mullen, Klaudia Nowak, Runjan Chetty
2022· article· en· Journal of Clinical Pathology· Medicine
machine prediction:candidate · noneconsensus · none
9
citations
afffundvenueaboutunlabeled
Management algorithms for metastatic prostate cancer
Shawn Malone, Bobby Shayegan, Naveen S. Basappa, Kim Chi, Henry Jacob Conter, Robert J. Hamilton +7 more
2019· review· en· Canadian Urological Association Journal· Medicine
machine prediction:candidate · noneconsensus · none
9
citations
affunlabeled
PTEN Loss in a Prostate Cancer Cohort From Jordan
Samir Al Bashir, Abdallah Alzoubi, Mahmoud A. Alfaqih, Khalid Kheirallah, Aya Smairat, Husam K. Haddad +4 more
2019· article· en· Applied immunohistochemistry & molecular morphology· Medicine
machine prediction:candidate · noneconsensus · none
9
citations
affunlabeled
Final analysis of phase III LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate + prednisone (AA+P) added to androgen deprivation therapy (ADT).
Karim Fizazi, NamPhuong Tran, Luis Fein, Nobuaki Matsubara, A. Rodrı́guez-Antolı́n, Mustafa Özgüroğlu +8 more
2019· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
9
citations

How this was built: Screen · Findings · About